Here are five key things investors need to know to start the trading day: Stocks rose Friday, wrapping up one of the most ...

Pfizer has axed its oral GLP-1 asset danuglipron after one patient had potential drug-induced liver injury in a phase 1 trial ...

Capping more than two years of stock-gyrating drama, Pfizer said Monday that it would stop development of danuglipron, its ...

A new Canadian guideline urges lifestyle interventions for obese children but also says today's new drugs might help kids ...

Ryan Rasmussen was determined to lose weight so he would be around to ski and spend time with his wife and children.

The decision to stop developing danuglipron adds to a string of setbacks in the pharmaceutical giant's bid to win a slice of ...

Pfizer on Monday said it has discontinued development of experimental weight-loss pill danuglipron after a trial patient ...

GLP-1s like Ozempic, as well as weight-loss surgery, are among the recommendations to treat childhood obesity in the first guideline update in Canada in almost 20 years.

India’s weight loss category is undergoing a dynamic transformation triggered by scientific improvements, pharma innovation, ...